The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.
In the trial, researchers will test how well Medera's SRD-001 gene therapy improves symptoms in heart failure patients with reduced ejection fraction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback